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        Introduction 
  The expansion of a polyglutamine (polyQ) tract in mutant 
proteins causes Huntington  ’  s disease (HD) and eight other 
known neurodegenerative diseases, including spinocerebel-
lar ataxia and spinobulbar muscular atrophy (  Zoghbi and 
Orr, 2000  ). The accumulation of expanded polyQ-containing 
proteins in the nucleus and the subsequent formation of nu-
clear inclusions are pathological hallmarks of these diseases 
(  Gatchel and Zoghbi 2005  ;   Butler and Bates, 2006  ). In the 
majority of polyQ diseases, the mutant proteins carry nuclear 
localization sequences and are therefore localized primarily 
in the nucleus. However, huntingtin (htt), a 350-kD protein 
with a polyQ domain in its N-terminal region, is predominantly 
localized in the cytoplasm. Generation of polyQ-containing 
N-terminal htt fragments by proteolysis leads to the accumu-
lation of toxic peptides (  Ellerby and Orr, 2006  ) that also 
form aggregates in the nucleus and the neuronal processes 
(neuropil aggregates), which include axons and dendrites 
(  DiFiglia et al., 1997  ;   Gutekunst et al., 1999  ;   Lunkes et al., 
2002  ;   Wellington et al., 2002  ;   Graham et al., 2006  ). Further-
more, polyQ expansion clearly causes protein misfolding 
and conformational alteration, leading to abnormal protein 
interactions and transcriptional dysregulation in the nucleus 
(  Zoghbi and Orr, 2000  ;   Sugars and Rubinsztein, 2003  ;   Li 
and Li, 2004  ;   Butler and Bates, 2006  ). Notably, the brains of 
HD patients at the early stage of disease contain more neuro-
pil aggregates than nuclear inclusions (  Gutekunst et al., 1999  ). 
Also, the progressive formation of neuropil aggregates is 
correlated with disease progression in transgenic mice (  Li 
et al., 1999  ,   2000  ;   Schilling et al., 1999  ;   Tallaksen-Greene 
et al., 2005  ), and these aggregates are associated with axonal 
degeneration in HD mouse models (  Li et al., 2001  ;   Yu et al., 
2003  ). Given the abundance of neuropil aggregates in HD 
patient brains, understanding the contribution of cytoplasmic 
htt to HD pathology is imperative. 
  Unlike nuclear inclusions, neuropil aggregates have not 
been studied extensively because of their small size. Although 
M
utant huntingtin accumulates in the neuronal 
nuclei and processes, which suggests that its 
subcellular localization is critical for the pathol-
ogy of Huntington  ’ s disease (HD). However, the contribu-
tion of cytoplasmic mutant huntingtin and its aggregates 
in neuronal processes (neuropil aggregates) has not been 
rigorously explored. We generated an intracellular anti-
body (intrabody) whose binding to a unique epitope of 
human huntingtin is enhanced by polyglutamine expansion. 
This intrabody decreases the cytotoxicity of mutant hun-
tingtin and its distribution in neuronal processes. When ex-
pressed in the striatum of HD mice via adenoviral infection, 
the intrabody reduces neuropil aggregate formation and 
ameliorates neurological symptoms. Interaction of the intra-
body with mutant huntingtin increases the ubiquitination of 
cytoplasmic huntingtin and its degradation. These ﬁ  ndings 
suggest that the intrabody reduces the speciﬁ  c neuro-
toxicity of cytoplasmic mutant huntingtin and its associated 
neurological symptoms by preventing the accumulation of 
mutant huntingtin in neuronal processes and promoting its 
clearance in the cytoplasm.
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  Results 
  Generation of an intrabody that 
preferentially binds mutant htt 
  Previously, we used a GST fusion protein containing the fi  rst 
256 amino acids of human htt as the antigen to generate rabbit 
antibody EM48 (  Fig. 1 A  ). This antigen lacks the polyQ and 
polyproline (polyP) domains but generates polyclonal EM48 
antibodies that selectively label mutant htt (  Gutekunst et al., 
1999  ). Using this same antigen, we obtained a mouse monoclo-
nal antibody, mEM48. Although mEM48 also reacts strongly 
with exon1 mutant htt containing 150Q in R6/2 mouse brain, it 
does not label normal htt at endogenous levels (  Fig. 1 B  ). Using 
1C2, a mouse monoclonal antibody that reacts with expanded 
polyQ tracts, we also observed similar nuclear and neuropil 
aggregates in N171-82Q mouse brains (Fig. S1 A, available 
at http://www.jcb.org/cgi/content/full/jcb.200710158/DC1). 
Furthermore, mutant htt tagged with the HA epitope at its 
C terminus formed intracellular aggregates in HEK293 cells, 
which were recognized by mEM48 and an antibody to the HA 
epitope (Fig. S1 B). To verify whether this monoclonal anti-
body binds mutant htt more tightly than normal htt, we used the 
in vitro synthesis method to generate N-terminal htt fragments 
(1  –  208 aa) containing different polyQ domains (23Q, 44Q, 
75Q, and 130Q), which were labeled by [ 
35 S]methionine. Auto-
radiography revealed htt fragments with longer polyQ domains 
synthesized in lesser amounts. The synthesized mutant htt did 
not show the aggregate form in the gel, perhaps because of the 
brief time allotted for its synthesis in vitro. Nonetheless, these 
mutant htt fragments with longer polyQ domains exhibited 
the role of htt aggregates remains controversial (  Saudou et al., 
1998  ;   Yamamoto et al., 2000  ;   Arrasate et al., 2004  ;   Chang 
et al., 2006  ), subcellular localization seems to be critical for 
the effects of mutant htt and its aggregates. Given the limited 
confi  nes of neuronal processes, it is conceivable that neuropil 
aggregates are sizeable enough to physically block intracellu-
lar transport. In any case, the formation of neuropil aggregates 
does refl  ect the transport and accumulation of toxic htt frag-
ments in neuronal processes and allows us to investigate the 
toxic effects of cytoplasmic mutant htt in the unique neuronal 
structure. The normal function of neuronal processes is depen-
dent on the proper transport of proteins and nutrients from the 
cell body to nerve terminals and may be more vulnerable than 
nuclear function to a variety of insults. Understanding the 
effects of cytoplasmic mutant htt in neuronal processes would 
be useful in the development of an effective treatment strategy 
for HD patients. 
  In the present study, we developed an intracellular anti-
body (intrabody) based on a compelling feature of one unique 
htt antibody, EM48, which preferentially reacts with mutant 
htt (  Gutekunst et al., 1999  ;   Graham et al., 2006  ). This intra-
body, when expressed in neurons, reduces the cytotoxicity of 
N-terminal mutant htt and decreases both the formation of 
neuropil aggregates and the neurological symptoms of HD 
mice. We further demonstrated that this intrabody promotes 
the degradation of cytoplasmic mutant htt by increasing its 
ubiquitination. These fi  ndings suggest that the intrabody spe-
cifi  cally targets mutant htt with abnormal conformation and 
can serve as a valuable tool to specifi  cally reduce the cytoplas-
mic neuropathology of HD. 
  Figure 1.       mEM48 preferentially binds mutant 
htt.   (A) An N-terminal fragment of human htt 
used to generate the mouse monoclonal an  ti      -
body mEM48. The gap represents the miss-
ing polyQ and polyP domains in this antigen. 
The black box indicates two glutamines (2Q). 
Amino acid numbers are indicated. (B) mEM48 
immunostaining of the hippocampal sections 
from HD transgenic (R6/2) and wild-type (WT) 
mice at 12 wk of age. Note that the antibody 
speciﬁ   cally reacts with intranuclear mutant 
htt aggregates and smaller neuropil aggre-
gates outside the nucleus. Bar, 5   μ  m. (C)  
35  S-
labeled N-terminal htt (aa 1  –  208) fragments 
containing various glutamine repeats (23, 44, 
75, and 130Q) were synthesized in vitro, re-
solved by SDS-PAGE, and revealed by auto-
radiography (24 h exposure). The same blot 
was then probed with mEM48 and visualized 
with ECL reagents (1 min exposure). Note that 
mEM48 preferentially reacts with N-terminal 
htt containing longer repeats.     805  SUPPRESSION OF NEUROPIL HTT AGGREGATES BY INTRABODY   •   Wang et al.
coexpressed with an N-terminal mutant htt (1  –  208 aa) con-
taining 130Q, scFv-EM48 colocalized with htt aggregates in 
both cultured HEK293 cells (  Fig. 2 B  ) and primary cortical neu-
rons (  Fig. 2 C  ). Coexpression of this intrabody with other polyQ 
disease proteins, such as ataxin-1 and ataxin-7, failed to show 
any colocalization with polyQ aggregates (Fig. S2, available 
at http://www.jcb.org/cgi/content/full/jcb.200710158/DC1), 
which indicates a specifi  c association between scFv-EM48 and 
htt. We next used coimmunoprecipitation to examine the inter-
action of scFv-EM48 with htt in transfected cells. Immuno-
precipitation of scFv-EM48 pulled down soluble mutant htt 
more mEM48 immunoreactivity, despite their lesser amounts 
on the blot (  Fig. 1 C  ). 
  This increased immunoreaction as a result of polyQ ex-
pansion led us to clone the cDNA for mEM48 from its hy-
bridoma cell line, with the aim of expressing this recombinant 
antibody in cells. We joined cloned cDNAs encoding variable 
light (V  L  ) and variable heavy (V  H  ) chains of mEM48 via an 
oligonucleotide linker, generating a 750-bp cDNA that en-
codes a single-chain Fv (scFv) for mEM48. This intrabody 
(scFv-EM48) was tagged with the HA epitope and expressed 
under the cytomegalovirus (CMV) promoter (  Fig. 2 A  ). When 
  Figure 2.       Generation and expression of 
scFV-EM48.   (A) Structure of the intrabody scFv-
EM48. The intrabody (251 aa) consists of vari-
able region heavy and light (V  H   and V  L  ) chains 
of the scFv for mEM48, which are linked by a 
Gly-Ser domain and tagged with the HA epi-
tope. Amino acid numbers are indicated. (B) Ex-
pression of scFv-EM48-HA in cultured HEK293 
cells. scFv-EM48-HA was either transfected alone 
or cotransfected with mutant htt (1  –  208 aa) 
containing 130Q. Cells were labeled with 
mouse anti-HA for scFv-EM48 and rabbit 
EM48 for htt. Note that scFv-EM48 is colocal-
ized with mutant htt (htt-130Q) in cytoplasmic 
aggregates. (C) Coexpression of scFv-EM48 
and mutant htt in cultured rat cortical neurons 
(arrows) also shows the colocalization of scFv-
EM48 with mutant htt. In B and C, cells were 
immunostained with mouse anti-HA (12CA5) 
and rabbit EM48. Bars, 10   μ  m. (D) West-
ern blot analysis of immunoprecipitates from 
transfected HEK293 cells that express scFv-
EM48-HA and exon1 htt with 130Q or 20Q. 
scFv-EM48 (scFv) was precipitated by the anti-
body (12CA5) to the HA epitope (bottom). The 
input and precipitates (IP) were then probed 
with rabbit EM48 (top). The arrow indicates 
soluble htt-20Q and the arrowhead indicates 
htt-130Q. The bracket indicates the stacking 
gel in which aggregated htt is seen. (E) Densi-
tometry of the ratio of precipitated htt to input 
from a representative experiment. Similar re-
sults were seen in two separate experiments.     JCB • VOLUME 181 • NUMBER 5 • 2008  806
blotting of brain tissues from YAC128 mice, which express full-
length human mutant htt with 128Q, and HD 150Q knock-in 
mice, which express full-length mouse mutant htt with 150Q. 
Although the 1C2 antibody, which reacts with expanded polyQ 
tracts, recognizes both human and mouse mutant htt, mEM48 
only reacts with human mutant htt (  Fig. 3 B  ). To verify that the 
presence of the VA residues may be critical for mEM48 immuno-
reaction, we synthesized a short peptide (16 aa) of human htt 
containing the VA residues (human peptides). For comparison, 
we used the peptides from the corresponding region of mouse 
htt that lacks the VA residues (mouse peptides). N-and C-terminal 
sequences of the fi  rst 170 amino acids, which are identical in 
human and mouse htt, were included as controls. Dot blots 
demonstrate that only the human peptide binds mEM48 (  Fig. 3 C  ). 
Moreover, the human but not the mouse peptide can inhibit the 
coimmunoprecipitation of mutant htt by mEM48 in transfected 
cells (  Fig. 3 D  ). We also have shown that mutant htt can be pre-
cipitated by the intrabody (scFv-EM48) in transfected cells 
(  Fig. 2 D  ), and this precipitation could be markedly attenuated 
by the human but not the mouse peptide (  Fig. 3 E  ). As VA resi-
dues are present in the human but not the mouse peptides, these 
fi  ndings suggest that the VA residues in exon1 of human htt are 
likely the epitope for mEM48 and its intrabody. However, the 
in transfected HEK293 cells (  Fig. 2 D  ). Some aggregated htt, 
which remained in the stacking gel, was coprecipitated with 
the scFv-EM48 as well, a result that is in agreement with our 
immunocytochemistry data showing that scFv-EM48 is pre-
sent in some htt aggregates. More importantly, there was very 
little normal htt in the immunoprecipitates, despite the fact that 
a substantial level of transfected normal htt could be detected 
by rabbit EM48. Densitometry of the ratio of precipitated/
input amount also shows that scFv-EM48 binds only weakly 
to normal htt, whereas it preferentially binds to mutant htt. 
  The preferential binding of the intrabody to mutant htt 
proves that the immunoreaction of mEM48 with htt is enhanced 
by polyQ expansion. Because mEM48 does not react with 
mouse htt and was generated with an antigen (2Q-htt) that lacks 
the polyQ and polyP tracts, we reasoned that comparison of the 
N-terminal sequences of 2Q-htt and htt from human and mouse 
might provide insight regarding the epitope for mEM48 (  Fig. 3 A  ). 
Because scFV-EM48 reacts with mutant htt exon1, we focused 
on the amino acid sequences in exon1 and found that two amino 
acid residues (VA) located after the polyP tract are present in 
both human htt and 2Q-htt but not mouse htt. To examine 
whether mouse mutant htt that carries an expanded polyQ tract 
also fails to react with mEM48, we performed mEM48 Western 
  Figure 3.       Identiﬁ   cation of the likely epitope for mEM48.  
(A) Comparison of N-terminal sequences of human and mouse htt 
and the antigen 2Q-htt. Two amino acid (VA) residues (italic 
type and underlined) are located after the polyP tract in human 
htt and 2Q-htt but are not present in mouse htt. Sequences in 
bold type were used for synthetic peptides. (B) Western blotting 
of cerebral cortical tissues from an HD YAC128 mouse, which 
expresses full-length mutant human htt, and from homozygous 
(Hom) or heterozygous (Het) HD 150Q knock-in (KI) mice, 
which express full-length mutant mouse htt. Note that the 1C2 
antibody recognizes mouse and human mutant htt, whereas 
mEM48 only recognizes human mutant htt. (C) Htt sequences 
shown in A were used to synthesize N-terminal (N), human, 
mouse, or C-terminal (C) peptides. These peptides were ap-
plied to the dot blot at different concentrations (1  –  100   μ  M), 
and the blot was subsequently probed with mEM48. Only 
the human peptide reacts with mEM48. (D) PC12 cell lysates 
containing transfected GFP-htt (1  –  208 aa with 130Q) were 
immunoprecipitated by mEM48 in the presence of the human 
or mouse peptide (10   μ  m). The blot was probed with rabbit 
EM48. Only the human peptide blocks the immunoprecipita-
tion. Control, immunoprecipitation without peptides. (E) Immuno-
precipitation of scFv-EM48-HA in transfected PC12 cells by 
mouse anti-HA. The blot was probed with mEM48 for the 
coprecipitated GFP-htt-130Q (top, Htt) and with anti-HA for 
scFv-EM48 (bottom). The human but not the mouse peptide 
markedly inhibited the coprecipitation of htt.     807  SUPPRESSION OF NEUROPIL HTT AGGREGATES BY INTRABODY   •   Wang et al.
imately 60  –  70% of HEK293 cells expressed transfected pro-
teins (unpublished data). Using SYTOX green, which labels 
dying cells, we observed that scFv-EM48 reduced the number 
of htt-transfected cells stained with SYTOX green compared 
with cells transfected with mutant htt and vector (  Fig. 4, 
A and B  ). We also examined the viability of htt-transfected cells 
using the MTS assay. The expression of htt-130Q reduced cell 
viability compared with htt-23Q transfection. However, this 
decrease in viability was improved by coexpression of scFv-
EM48 (  Fig. 4 B  ). 
human sequences that include VA (PPGPAVA) also differ from 
the mouse sequences (LPGPA) and might also be the source of 
the preferential immunoreactivity with mEM48. 
  Intrabody inhibits htt cytotoxicity 
  If scFv-EM48 indeed binds tightly to mutant human htt, it 
may prevent htt from binding to other proteins, thereby reduc-
ing htt toxicity. We transfected HEK293 cells with N-terminal 
htt (1  –  208 aa) that contained either 23Q or 130Q. scFv-EM48 
was also coexpressed to assess its protective effect. Approx-
  Figure 4.       scFv-EM48 suppresses cytotoxicity of mutant htt.   (A and B) HEK293 cells were transfected with htt (1  –  208 aa) containing 23Q or 130Q and 
scFv-EM48 (+scFv). Cotransfection with a vector served as a control. SYTOX green staining of transfected HEK293 cells is shown in A, in which greater ﬂ  uo-
rescence is correlated with increased cell death. In B, the relative ﬂ  uorescence values of SYTOX green  –  containing cells were obtained from six transfection 
experiments. Cell viability was also measured by a modiﬁ  ed MTT assay (MTS) and expressed as absorbance at 490 nm (OD490 nm absorbance values; 
  n   = 9, P   <   0.05). The decreased MTS correlates with reduced cell viability. (C) Immunoﬂ  uorescent staining of cultured rat cortical neurons (7 days in vitro) 
that express transfected htt (htt-23Q or htt-130Q) or scFv-EM48 alone (top). Htt was labeled by rabbit EM48, and scFv-EM48-HA was labeled by antibody 
to the HA epitope. Note that mutant htt formed neuritic aggregates and caused neuritic fragmentation in transfected cells. Coexpression of scFv-EM48 
reduced htt aggregation in neurites and degeneration of cultured neurons (bottom). Nuclei were stained with Hoechst blue dye in the merged images. 
(D) The percentage of cells showing disrupted neurites and fragmented nuclei. Data were obtained by counting 156  –  198 transfected cells in three transfection 
experiments. The data are presented as means   ±   standard error. *, P   <   0.05; **, P,   <   0.01. Bars: (A) 100   μ  m; (C) 8   μ  m.     JCB • VOLUME 181 • NUMBER 5 • 2008  808
  Intrabody suppresses neuropil aggregates 
in HD mouse brain 
  Although the results in   Fig. 4   established the protective ef-
fects of scFv-EM48 in cultured cells, whether scFv-EM48 
could confer protection in HD mouse brains remained to be 
seen. To test the effects of scFv-EM48 in the brain, the pro-
tein must be delivered via viral infection and microinjection 
of a small volume (1  –  2   μ  l per injection). However, conven-
tional adenoviral and lentiviral vectors failed to yield a suf-
fi  ciently high titer of viral scFv-EM48. Intrabody instability 
  To examine whether scFv-EM48 also reduces the neuro-
toxicity of mutant htt, we cotransfected scFv-EM48 with htt-130Q 
in cultured rat cortical neurons. Similar to previously published 
fi  ndings (  Saudou et al., 1998  ;   Li et al., 2001  ), mutant htt could lead 
to neuritic disruption (  Fig. 4 C  ) and pyknotic nuclei (Fig. S3, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200710158/DC1). 
Expression of scFv-EM48 alone did not affect the morphology of 
cultured neurons, but its coexpression with htt-130Q signifi  cantly 
reduced the number of htt-transfected neurons with disrupted neu-
rites or fragmented nuclei (  Fig. 4, C and D  ; and S3). 
  Figure 5.       scFv-EM48 reduces neuropil aggre-
gates in HD mouse brains.   (A) Immunostaining 
of the mouse brain with rabbit anti-HA (red) and 
mouse anti-NeuN (green) conﬁ  rms  that  scFv-
EM48-HA is expressed in neurons. Merged im-
age is also shown. (B and C) Immunostaining 
of the striatum of R6/2 mice (B) and the cortex 
of N171-82Q HD mice that were injected with 
adenoviral vector (control virus) or adenoviral 
scFv-EM48 (C). Rabbit EM48 was used to stain 
transgenic htt (green). scFv-EM48 staining is 
not shown separately but can be seen in the 
merged images in which scFv-EM48-HA (red) is 
stained by mouse antibody to the HA epitope, 
and nuclei (blue) were revealed with Hoechst 
dye. Note that small neuropil aggregates were 
decreased in the adenoviral scFv-EM48  – 
injected area. Bars, 5   μ  m. (D) Quantitative as-
sessment of neuropil aggregate density in R6/2 
and N171-82Q mice. The values represent 
the number of neuropil aggregates per image 
(630  ×  ) relative to the noninjected contralateral 
area. The data are presented as means   ±   stan-
dard error. **, P   <  0.01.     809  SUPPRESSION OF NEUROPIL HTT AGGREGATES BY INTRABODY   •   Wang et al.
effects of scFv-EM48 after its delivery to the striatum. To this 
end, we bilaterally injected adenoviral scFv-EM48 into the stri-
atum (1.25   μ  l per site) of 10-wk-old N171-82Q mice. As a con-
trol, HD mice were injected with the same amount of adenoviral 
vector. After 8 wk, we observed signifi  cant improvements in 
gait function for the HD mice that had been injected with adeno-
viral scFv-EM48 (  Fig. 6, A and B  ). Measures included stride 
length (50.82   ±   1.95 mm [  n   = 11] for scFv-EM48 vs. 42.8   ±   
3.1 mm [  n   = 9] for control virus; P   <   0.05). Also, the RotaRod 
performance of HD mice was improved. For example, the times 
on the RotaRod were 93.7   ±   4.32 s (  n   = 10) for scFv-EM48  – 
injected mice and 59.8   ±   1.39 s (  n   = 9) for control virus-injected 
mice (P   <   0.05) on trial day 3 (  Fig. 6 C  ). However, we did not 
observe a signifi  cant improvement in body weight or survival of 
N171-82Q mice injected with adenoviral scFv-EM48 (  Fig. 6 D  ). 
The selective protection of scFv-EM48 against motor defi  cits is 
likely caused by the limited expression of this intrabody in the 
striatum and its selective effect on cytoplasmic mutant htt. This 
fi  nding also suggests that the expression of mutant htt in the nu-
cleus and in brain regions other than the striatum can contribute 
to severe neurological phenotypes. 
  We also performed immunofl  uorescence double-labeling 
of viral-infected PC12 cells and found that scFv-EM48 
decreased the number of htt aggregates in neurites (  Fig. 7, 
A and B  ). To verify that scFv-EM48 reduces the distribution 
of soluble mutant htt in the neurites, we measured the ratio of 
htt  ’  s neuritic signal to its cell body signal (  McGuire et al., 
2006  ). As expected, scFv-EM48 signifi  cantly decreased the 
number of cells with neuritic aggregates (38.8   ±   3.7% for vec-
tor control vs. 9.2   ±   0.5% for scFv-EM48;   n   = 3;   P   <   0.01). 
Also, the relative neuritic distribution of mutant htt in PC12 
cells was reduced by scFv-EM48 (ratio of neuritic signal/cell 
body signal: 0.35   ±   0.06 for scFv-EM48 vs. 0.82   ±   0.04 for 
vector control;   n   = 10; P   <   0.01;   Fig. 7 C  ). These fi  ndings are 
consistent with the in vivo inhibition of neuropil aggregates by 
scFv-EM48 in HD mouse brains (  Fig. 5  ) and in cultured corti-
cal neurons (Fig. S3). 
  Intrabody promotes the degradation of 
mutant htt 
 The  signifi  cant reduction of neuropil aggregates and the im-
provement in neurological symptoms associated with scFv-
EM48 led us to explore the mechanism underlying this protection. 
The decreased amount of neuropil aggregates in HD mouse 
brains could be caused by the reduced distribution of mutant 
htt to neuronal processes and/or increased htt clearance in the 
cytoplasm. We therefore fractionationed synaptosomes from 
the striatal tissue of N171-82Q mice, in which the protein 
level of mutant htt is comparable to endogenous htt (  Schilling 
et al., 1999  ). As shown previously (  Schilling et al., 1999  ), a 
cleavage product smaller than transgenic mutant htt (   47  kD) 
is visible in the brain lysates of HD mice. In HD striatal tis-
sues expressing scFv-EM48, this cleaved product and two ad-
ditional smaller products (  Fig. 8 A  , arrowheads) are more 
abundant than in those brains injected with control adenovirus. 
This difference suggests that the interaction of the intrabody with 
mutant htt in the cytosolic region may facilitate the degradation 
in cells and viral toxicity very likely impose a considerable 
obstacle to using these viral vectors. Next, we tried a helper-
dependent adenoviral vector in which the viral coding se-
quences have been replaced with noncoding human genomic 
DNA (  Toietta et al., 2002  ,   2005  ). The elimination of all viral 
protein-coding sequences in this vector results in less cyto-
toxicity and long-term expression of transgenes compared with 
the earlier-generation adenoviral vectors (  Toietta et al., 2002  , 
  2005  ). Western blot analysis confi  rmed that this adenoviral 
vector expressed scFv-EM48 protein of the correct size in 
cultured cells (Fig. S4, available at http://www.jcb.org/cgi/
content/full/jcb.200710158/DC1). 
 Using  immunofl  uorescence double-labeling with anti-
bodies to the HA epitope and to a neuronal marker (NeuN), we 
fi  rst confi  rmed that scFv-EM48 was expressed in neurons after 
microinjection into the mouse brain (  Fig. 5 A  ). Unlike trans-
fected cells, in which mutant htt can form large inclusions 
in the cell bodies, neurons in HD brains show aggregates in 
the nucleus and neuronal processes (  DiFiglia et al., 1997  ; 
  Gutekunst et al., 1999  ;   Li et al., 1999  ). After confi  rmation of 
neuronal scFv-EM48 expression, we next injected adenoviral 
scFv-EM48 into the striatum of 7-wk-old R6/2 mice. At this 
age, R6/2 mice begin to develop prominent htt nuclear and 
neuropil aggregates, and stereotaxic injection into the mouse 
striatum becomes feasible. 4 wk after the procedure, we found 
that the number of neuropil aggregates in the injected area had 
been reduced dramatically when compared with the non-
injected region (  Fig. 5 B  ). There appeared to be a slight reduc-
tion of nuclear staining as well, but this difference was diffi  cult 
to quantify by immunostaining. 
  We also injected adenoviral scFv-EM48 into N171-82Q 
mice. This HD mouse model expresses the fi  rst 171 amino acids 
of human htt with 82Q and also demonstrates obvious neuropil 
aggregates in the brain (  Schilling et al., 1999  ). We found that 
adenoviral scFv-EM48 injected into the cortex of N171-82Q 
mice over a period of 6 wk reduced the abundance of neuropil 
aggregates (  Fig. 5 C  ). 
  To verify the specifi  city of adenoviral scFv-EM48, we 
also injected mice from both strains with a control virus that 
does not express scFv-EM48. We quantifi  ed the neuropil aggre-
gate density per image (630  ×  ) and normalized this quantity by 
the density of neuropil aggregates in the noninjected contra-
lateral region. This method allowed us to mitigate the infl  uence 
of variations in immunostaining and brain section preparation. 
Compared with control virus, injection of adenoviral scFv-
EM48 signifi  cantly reduced neuropil aggregates in R6/2 and 
N171-82Q mouse brains (P   <   0.01;   n   = 10 for adenoviral scFv-
EM48 vs.   n   = 6 for control;   Fig. 5 D  ). 
  Both R6/2 and N171-82Q mice widely express mutant htt 
in various brain regions. As a result, they develop severe neuro-
logical symptoms and early death by the age of 3  –  6 mo (  Davies 
et al., 1997  ;   Schilling et al., 1999  ). However, inhibiting the ex-
pression of transgenic htt via siRNA in the striatum of N171-
82Q mice, which exhibit a slower disease progression than R6/2 
mice, leads to an improvement in their motor function (  Harper 
et al., 2005  ). Therefore, we speculated that N171-82Q mice 
would also be good candidates for testing the in vivo protective JCB • VOLUME 181 • NUMBER 5 • 2008  810
  The increased htt degradation in synaptosomes of HD mice 
injected with adenoviral scFv-EM48 led us to test the possibility 
that scFv-EM48 can promote the degradation of mutant htt. 
We coexpressed adenoviral vector or scFv-EM48 with GFP-
htt-130Q (1  –  208 aa with 130Q) in cultured PC12 cells. GFP-
htt-130Q is mainly distributed in the cytoplasm and forms 
cytoplasmic aggregates. Thus, cytoplasmic proteins of PC12 
cells were isolated as soluble and nonsoluble or pellet fractions, 
with the expectation that the latter would be enriched for aggre-
gated htt or htt that is bound tightly to the intrabody. Total cell 
lysates containing scFv-EM48 show more degraded htt pro-
ducts than control cell lysates (  Fig. 8 B  ). Consistent with the 
fact that more scFv-EM48 was present in the pellet fraction than 
in the soluble fraction, more degraded htt products were also 
of mutant htt. Importantly, compared with the samples from 
HD mice that were injected with adenoviral vector, the ratio 
(mean   ±   SEM,   n   = 3) of either soluble (control vs. scFv-EM48: 
0.528   ±   0.04 vs. 0.279   ±   0.03, respectively) or oligomeric 
(1.28   ±   0.11 vs. 0.77   ±   0.06) htt to the synaptic protein syn-
taxin is decreased in the synaptosomal fractions of HD mice 
that had been injected with adenoviral scFv-EM48 (  Fig. 8 A  , 
bottom). Because the intrabody cannot enter the nucleus to af-
fect nuclear mutant htt, there was no signifi  cant difference in 
the levels of aggregated htt in nuclear fractions of HD mice in-
jected with adenoviral control vector or scFv-EM48 (  Fig. 8 A  ). 
Thus, this in vivo evidence also indicates that scFv-EM48 can 
reduce the distribution of mutant htt in nerve terminals in HD 
mouse brains. 
  Figure 6.       scFv-EM48 alleviates the motor 
deﬁ  cits of N171-82Q mice.   (A) Footprint trac-
ings of wild-type (WT), N171-82Q mice (HD), 
and N171-82Q mice injected with adeno-
viral scFv-EM48 (HD + scFv) or an adenoviral 
vector (HD + control). (B) Mean stride lengths 
(in millimeters) of the mice in A show that the 
abnormal gait seen in N171-82Q mice is 
partially reversed by adenoviral scFv-EM48. 
(C) Accelerating RotaRod testing of wild-type 
(WT) and N171-82Q mice (HD) demonstrates 
an improvement in RotaRod performance (time 
on the rod) for N171-82Q mice (HD + scFv) 
that had received adenoviral scFv-EM48 injec-
tions in their striatum. In all trials,   n   = 9  –  11 
mice. P   <   0.05 as compared with N171-82Q 
mice injected with adenoviral vector control 
(HD + control). (D) Survival plot and body 
weight (in grams) of wild-type (WT), N171-
82Q (HD), and N171-82Q mice injected with 
adenoviral scFv-EM48 (HD + scFv) or an adeno-
viral vector (HD + control). The data are pre-
sented as means   ±   standard error. *, P   <   0.05; 
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enriched in mutant htt and scFV-EM48 without detectable tubu-
lin (  Fig. 8 B  ), we probed this fraction with an antibody to 
ubiquitin and observed an obvious increase in the amount of 
ubiquitinated products (  Fig. 8 D  , left). Immunoprecipitation of 
htt by EM48 also shows more ubiquitinated products in the 
presence of scFv-EM48 (  Fig. 8 D  , right). These fi  ndings are 
consistent with the increased degradation of mutant htt in the 
pellet fraction seen in   Fig. 8 B  . To provide direct evidence that 
scFv-EM48 increases the ubiquitination of mutant htt, we per-
formed immunofl  uorescent staining of PC12 cells that were 
infected by adenoviral GFP-htt-130Q alone or with adenoviral 
scFv-EM48. More infected cells contained ubiquitinated aggre-
gates in the presence of scFv-EM48 (73.9   ±   2.4%) than in the 
absence of scFv-EM48 (49.8   ±   2.8%; P   <   0.05,   n   = 3;   Fig. 8 E  ). 
detected in the pellet fraction, which suggests that the associa-
tion of scFv-EM48 with mutant htt is required for the degrada-
tion of mutant htt. We then performed pulse-chase experiments 
to measure the half-life of mutant htt. In the presence of scFv-
EM48, the half-life of mutant htt is obviously shorter than in the 
absence of scFv-EM48 (  Fig. 8 C  ). For example, at 4 h after 
chasing, 46.9   ±   2.62% of radiolabeled mutant htt remained in 
the presence of scFv-EM48 compared with 74.1   ±   3.2% (P     <    0.05, 
  n   = 3) of mutant htt in the absence of scFv-EM48 (P   <   0.05, 
  n   = 3). It is possible that the binding of scFv-EM48 alters the 
conformation of mutant htt and leads to its degradation via 
the ubiquitin  –  proteasome system. If true, we should see in-
creased ubiquitination of mutant htt in the presence of scFv-
EM48. Because the cytoplasmic nonsoluble or pellet fraction is 
  Figure 7.       scFv-EM48 reduces the distribution of mutant htt in the neurites of PC12 cells.   (A) PC12 cells were infected by adenoviral htt-130Q only. 
Two images (right and left) from independent experiments are shown. The middle image is a merged image showing nuclear (blue) staining for the left image. 
Arrows indicate htt aggregates in neurites. (B) PC12 cells were coinfected with adenoviral htt and adenoviral scFv-EM48-HA and then stained with rabbit EM48 
for htt and mouse anti-HA for scFv-EM48. (top) Cells coexpressing htt-130Q and scFv-EM48. (bottom) Cells coexpressing htt-23Q and scFv-EM48. Note that 
the neuritic aggregates formed by htt-130Q are reduced by scFv-EM48. Bars, 10   μ  m. (C) Quantitative assessment of the percentage of transfected PC12 cells 
showing neuritic aggregates and the ratios of neuritic htt signals to cell body signals. The data are presented as means   ±   standard error. **, P   <   0.01.     JCB • VOLUME 181 • NUMBER 5 • 2008  812
intrabody (NAC32) against     -synuclein (  Lynch et al., 2008  ), we 
found that this control intrabody neither associated with htt ag-
gregates nor reduced htt levels in transfected cells (Fig. S5, avail-
able at http://www.jcb.org/cgi/content/full/jcb.200710158/DC1). 
Collectively, these results indicate that the intrabody scFv-EM48 
In control cells that only expressed mutant htt, htt aggregates, 
which were either ubiquitin negative or weakly labeled by anti-
ubiquitin, were also found in neurites, in contrast to scFV-
EM48  –  containing cells in which most htt aggregates were 
ubiquitinated and remained in the cell body. Using a control 
  Figure 8.       ScFV-EM48 promotes the degradation of mutant htt.   
(A) Western blot of total lysates (T) and cytosolic (C), 
synaptosomal (S), and nuclear (N) fractions of striatal tissues 
from N171-82Q mice that had been injected with adenoviral 
vector (control) or scFv-EM48. Oligomeric mutant htt is pre-
sent in the stacking gel (bracket). Arrows indicate transgenic 
htt and its cleaved product and arrowheads indicate addi-
tional degraded products. The same samples were probed 
with rabbit EM48 to htt and antibodies to the synaptic protein 
syntaxin, the nuclear protein TBP, and the cytoplasmic pro-
tein glyceraldehyde-3-phosphate dehydrogenase (GAPDH). 
The ratios (mean   ±   SEM,   n   = 3) of oligomeric or soluble htt 
to syntaxin were obtained using densitometry and are pre-
sented beneath the blots. *, P   <   0.05. (B) Total lysates (T), 
cytoplasmic soluble (S), and pellet (P) fractions of PC12 cells 
coinfected by adenoviral GFP-htt-130Q and adenoviral vec-
tor (control) or scFv-EM48 were analyzed by Western blotting 
with mEM48 and antibodies to HA for scFV-EM48 or tubulin. 
Arrowheads indicate degraded htt products. (C) Pulse chase 
of mutant htt (GFP-htt-130Q) in adenoviral vector (control)  –   or 
scFv-EM48  –  infected PC12 cells (top). Arrowhead indicates 
a nonspeciﬁ  c band. Quantiﬁ  cation of the percentage of re-
maining  
35  S-labeled htt signal at different chase times (bottom, 
  n   = 3). *, P   <   0.05  .   (D) The pellet fractions described in B 
were analyzed by Western blotting with anti-ubiquitin (left) or 
subjected to EM48 immunoprecipitation (right). The precipi-
tates were analyzed by Western blotting with anti-ubiqutin. 
The brackets indicate the increased amount of ubiquitinated 
products in the presence of scFv-EM48. Precipitated IgG is 
also indicated. (E) Immunoﬂ  uorescent staining of PC12 cells, 
which express GFP-htt-130Q alone or with scFV-EM48, with 
rabbit anti-ubiquitin and mEM48 or mouse anti-HA. In the 
absence of scFv-EM48, mutant htt forms aggregates (arrows) 
that localize to the cell body and neurites (top). In the pres-
ence of scFV-EM48, htt aggregates (arrows) remain in the cell 
body and can be labeled by antibodies to ubiquitin (middle) 
or to the HA epitope in scFv-EM48 (bottom). Bars, 8   μ  m.     813  SUPPRESSION OF NEUROPIL HTT AGGREGATES BY INTRABODY   •   Wang et al.
ropil aggregates (  Schilling et al., 1999  ). In addition, the in vivo 
effect of scFv-EM48 on mutant htt is persuasively indicated by 
its preferential binding to mutant htt and its in vitro protection 
against htt toxicity. 
  We found that scFv-EM48 did not signifi  cantly reduce the 
formation of nuclear inclusions. It is conceivable that cyto-
plasmic scFv-EM48 cannot enter the nucleus, where these 
htt fragments have already accumulated. Alternatively, small 
htt fragments can readily enter the nucleus, and expanded polyQ 
tracts prevent their export from the nucleus (  Cornett et al., 
2005  ), whereas the transport of mutant htt to neuronal pro-
cesses is dependent on its interactions with traffi  cking proteins. 
Although scFv-EM48 binds an epitope that may not be involved in 
interactions with other proteins, its interaction with mutant htt 
can cause a conformational change that could alter the associa-
tion of htt with other proteins, such as traffi  cking proteins. Im-
portantly, interactions of intrabody with htt can alter the stability 
of htt, as our studies demonstrate that the interaction of scFv-
EM48 with mutant htt increases the ubiquitination of mutant htt 
and reduces its half-life. It has been shown previously that some 
intrabodies can reduce htt aggregation (  Lecerf et al., 2001  ; 
  Khoshnan et al., 2002  ;   Colby et al., 2004  ) or decrease the level 
of exon1 mutant htt (  Wolfgang et al., 2005  ). Our fi  ndings sug-
gest that the interaction of scFv-EM48 with mutant htt could alter 
htt  ’  s conformation and/or make mutant htt more accessible to 
the ubiquitin  –  proteasome system, thereby promoting its degra-
dation. It would be interesting to investigate whether previously 
reported htt intrabodies also act on htt via this mechanism. 
  It is known that cytoplasmic mutant htt is transported 
within neuronal processes (  Gunawardena et al., 2003  ;   Szebenyi 
et al., 2003  ). In the present study, we present the fi  rst in vivo evi-
dence that the interaction of intrabody with cytoplasmic mutant 
htt reduces its distribution in the neuronal processes and amelio-
rates neurological symptoms in HD mice. Decreasing the dis-
tribution of mutant htt in neuronal processes can reduce the 
cytoplasmic effects of htt on mitochondria, traffi  cking, and syn-
aptic transmission to improve neuronal function. Suppressing 
neuropil aggregate formation may be particularly relevant in 
treating the specifi  c neuropathology of both HD and spinobulbar 
muscular atrophy, in which neuropil aggregates have also been 
observed (  Parker et al., 2001  ;   Piccioni et al., 2002 ). Although  sol-
uble mutant htt can affect intracellular traffi  cking (  Gunawardena 
et al., 2003  ;   Szebenyi et al., 2003  ;   Gauthier et al., 2004  ;   Trushina 
et al., 2004 ), polyQ aggregates in the neuronal processes can also 
physically block intracellular transport ( Piccioni et al., 2002 ;  Lee 
et al., 2004  ;   Chang et al., 2006  ) and are associated with axonal 
degeneration in polyQ disease models (  Li et al., 2001  ;   Parker 
et al., 2001  ;   Yu et al., 2003  ). Because neuropil aggregates are 
more abundant than nuclear inclusions in the brains of presymp-
tomatic and early-stage HD patients (  Gutekunst et al., 1999  ), 
suppressing their formation could be benefi  cial in terms of 
reducing neuronal dysfunction before degeneration occurs. 
Because we have shown that scFv-EM48 is specifi  c to mutant 
htt, the present fi  ndings suggest that intracellular antibodies to 
specifi  c polyQ proteins can make useful tools for unraveling 
pathological events caused by polyQ proteins, and may also pave 
the way for development of effective polyQ disease therapies. 
can reduce the accumulation of mutant htt in neuronal processes 
while promoting the ubiquitination and degradation of mutant 
htt in the cytoplasm. 
  Discussion 
  Here, we demonstrate that the intrabody scFv-EM48 preferen-
tially binds mutant htt and inhibits the specifi  c neuropathology 
of HD. This intrabody provides a useful tool for suppressing the 
cytoplasmic toxicity of mutant htt, thereby allowing us to dif-
ferentiate the cytoplasmic from the nuclear effects of mutant 
htt. The present study also suggests that the abnormal confor-
mation of mutant htt itself makes an effective therapeutic target 
that is highly specifi  c. 
  Normal levels of htt are critical for neurogenesis and em-
bryonic development (  White et al., 1997  ), and conditional 
knockout mice, in which htt expression has been inactivated, 
show degeneration of neuronal cells (  Dragatsis et al., 2000  ). 
Although these fi  ndings suggest that a loss of function may be 
involved in HD pathology, there is considerable evidence that 
the polyQ expansion in mutant htt results in a gain of toxic 
function. For example, even in those HD mouse models ex-
pressing endogenous htt at normal levels, transgenic mutant htt 
leads to neuropathology and neurological symptoms (  Davies 
et al., 1997  ;   Schilling et al., 1999  ;   Graham et al., 2006  ). The gain-
of-toxic-function theory provides a rationale for suppressing 
the expression of the transgene in HD mice (  Yamamoto et al., 
2000  ;   Harper et al., 2005  ). However, such suppression cannot 
distinguish the effects of mutant htt in the nucleus versus the 
cytoplasm. An alternative approach has been targeting nuclear 
export sequences to transgenic polyQ proteins, but expanded 
polyQ proteins could not be completely directed to the cyto-
plasm (  Jackson et al., 2003  ;   Benn et al., 2005  ). 
  Intracellular expression of intrabodies has proved suc-
cessful at blocking the toxic effects of mutated proteins or 
pathogenic agents with high selectivity (  Hudson and Souriau, 
2003  ;   Lobato and Rabbitts, 2004  ). The interaction of intra-
bodies with their targets can prevent the binding of these targets 
to other proteins (  Dorai et al., 1994  ). Furthermore, intrabodies 
in both cellular and   Drosophila melanogaster   HD models have 
shown encouraging protective effects (  Lecerf et al., 2001  ; 
  Khoshnan et al., 2002  ;   Colby et al., 2004  ;   Miller et al., 2005  ; 
  Wolfgang et al., 2005  ), but such studies have not been extended 
to HD mouse brains. Unlike most intrabodies used previously, 
our intrabody scFv-EM48 binds to a unique epitope in human 
htt and preferentially interacts with mutant htt. Because the 
polyQ domain is not the epitope for this interaction, the ex-
panded polyQ-mediated conformational alteration must lead to 
the increased binding of mutant htt to scFv-EM48. This is also 
consistent with the notion that polyQ expansion enhances the 
interactions of mutant htt with other molecules. This unique 
property allows for the selective reduction of mutant htt and its 
toxic effects, without interfering with the critical function of 
normal htt. In support of this idea, we provide in vivo evidence 
that scFv-EM48 can suppress formation of neuropil aggregates 
in the brain and ameliorate neurological symptoms in N171-
82Q mice, in which transgenic mutant htt forms abundant neu-JCB • VOLUME 181 • NUMBER 5 • 2008  814
63  ×   LD-Achroplan 0.75 lens (Carl Zeiss, Inc.). The images were captured 
with a digital camera (Orca-100; Hamamatsu) and Openlab software 
(PerkinElmer). We performed quantiﬁ  cation of htt aggregates and htt signal 
in neurites and the cell body of PC12 cells using the same method de-
scribed previously (  McGuire et al., 2006  ). We counted 10 different ﬁ  elds 
from each sample. Data were obtained by counting 81  –  93 cells per group 
in three experiments and are presented as the percentage of cells with dis-
rupted neurites or fragmented nuclei. 
  Stereotaxic injection of scFv-EM48 into mouse brain 
  We anesthetized mice with intraperitoneal injections of 2.5% avertin 
(0.012 ml/g body weight) and performed lateral stereotaxic injections of viral 
vectors. Using a 5-  μ  l syringe (Hamilton), we injected 1.25   μ  l of adenoviral 
scFv-EM48 or control viral vector (6   ×   10 
9   viral particles per microliter) into 
the striatum or cortex according to the following coordinates: for the stria-
tum, 0.8 mm rostral to bregma, 2.0 mm lateral to the midline, and 3.5 mm 
ventral to the dural surface; for the cortex, 1 mm rostral to bregma, 2.0 mm 
lateral to the midline, and 1.5 mm ventral to the dural surface. The injection 
rate was 0.5   μ  l/2 min, and the needle was left in place for an additional 
5 min before being removed. Body weight, growth, behavior, and motor func-
tion were examined using standard assays (  Davies et al., 1997  ;   Schilling 
et al., 1999  ). After 4  –  6 wk, the injected animals were killed and subjected to 
immunohistochemical staining. The density of neuropil aggregates was de-
termined by counting the number of htt-positive aggregates per image, and 
this is represented as a percentage of the noninjected contralateral region. 
The adenoviral scFv-EM48  –  injected group contained 10 mice, whereas the 
control adenoviral vector  –  injected group consisted of six mice. 
  Microscopy 
  All imaging was done at room temperature,     26  °  C. Immunocytochemi-
cal analysis of cultured cells and mouse brain tissues was performed as 
described previously (  Li et al., 2000  ,   Shin et al., 2005  ). Light micro-
graphs were taken using a microscope (Axiovert 200 MOT) equipped 
with a digital camera (Orca-100) and image acquisition software (Open-
lab). A 20  ×   LD-Achroplan 0.4 NA or 63  ×   0.75 NA oil immersion ob-
jective lens (both from Carl Zeiss, Inc.) was used for light microscopy. 
For immunoﬂ  uorescent staining, species-speciﬁ  c ﬂ  uorescein- or Texas red  –
  conjugated secondary antibodies (Jackson ImmunoResearch Laboratories) 
were applied for 1 h at room temperature followed by counterstaining 
with Hoechst dye. Enhanced GFP was imaged using 488-nm excitation 
and a 500  –  530-nm band-pass ﬁ  lter, and RFP was imaged using 543-nm 
excitation and a 565  –  615-nm band-pass ﬁ  lter. The ﬁ  gures were created 
using Photoshop 7.0 software (Adobe) and, in some cases where the 
brightness and contrast of the whole image needed adjustment, we used 
the brightness/contrast adjustment function. 
  Behavioral analysis 
  To examine gait function, we measured stride length. Mice injected bilater-
ally with adenoviral virus at 10 wk of age were analyzed after 8 wk of in-
jection. Mice were allowed to walk across a paper-lined chamber and into 
an enclosed box. After one practice run, tracings for front and rear foot-
prints for each mouse were measured. Measurements were averaged and 
the data were presented as stride length in millimeters. To measure RotaRod 
performance, mice were trained for 5 min on three separate days on a 
RotaRod device (Rotamex 4/8; Columbus Instruments) at 5 rpm and tested 
at speeds of 4  –  40 rpm over a 5-min period. Latency to fall was recorded. 
Mice were allowed 10  –  20 min to recover between trials. Survival and 
body weight of mice were also monitored. Uninjected WT mice,   n   = 11; 
N171-82Q mice injected with adenoviral scFv-EM48,   n   = 10; N171-82Q 
mice injected with adenoviral vector control,   n   = 9; uninjected HD-N171-
82Q mice,   n   = 9. 
  Dot blot analysis 
  A Hybond-P membrane (GE Healthcare) was rinsed in methanol and soaked 
in PBS. 2   μ  l of peptide solution in PBS were spotted on the x axis, with dif-
ferent dilutions (0, 1, 5, 25, 50, and 100   μ  M) on the y axis. The membrane 
was dried and blocked sequentially in 3% BSA and 5% milk in PBS for 1 h 
and then incubated overnight with mEM48 antibody at 4  °  C. The membrane 
was then rinsed with 5% milk/PBS three times and incubated with peroxidase-
conjugated anti-mouse secondary antibody (Jackson ImmunoResearch 
Laboratories) at a 1:10,000 dilution in 5% milk/PBS for 1 h. The mem-
brane was developed using ECL Plus reagents (GE Healthcare). 
  Protein binding assays and fractionation 
  We performed immunoprecipitation of transfected HEK293 and infected PC12 
cells using the same method described previously (  McGuire et al., 2006  ). 
  Materials and methods 
  Reagents and animals 
  Transgenic mice (R6/2 and N171-82Q) were obtained from The Jackson 
Laboratory and maintained in the animal facility at Emory University. Cere-
bral cortical tissues from YAC128 transgenic mice were provided by 
M. Hayden (University of British Columbia, Vancouver, Canada). Brain tissues 
from HD 150Q knock-in mice were obtained as described previously 
(  Zhou et al., 2003  ). Htt peptides (14  –  18 residues) from different regions of 
N-terminal human and mouse htt were synthesized by the Biochemical 
Core Facility at Emory University. In vitro synthesized htt was generated in 
50  μ  l of in vitro SP6-Transcription/Translation kit (Roche) with [ 
35  S]methionine 
and PRK plasmids (1   μ  g each) encoding different forms of htt. The reaction 
was incubated at 30  °  C for 1 h. 20   μ  l of reaction was subjected to SDS-
PAGE. The rabbit and mouse antibodies to htt were generated as described 
previously (  Zhou et al., 2003  ). Other antibodies used include mouse mono-
clonal antibodies to     -tubulin (Sigma-Aldrich), NeuN (Millipore), syntaxin 
(Sigma-Aldrich), TBP (Santa Cruz Biotechnology, Inc.), GAPDH (Millipore), 
and ubiquitin (Dako). PRK expression vectors encoding N-terminal htt 
(208 aa) with 23Q or 130Q and adenoviral htt constructs encoding GFP – 
N-terminal htt (1  –  208 aa) with 23Q or 130Q were described previously 
(  Shin et al., 2005  ). FLAG-tagged pcDNA  –  ataxin-1 82Q plasmid was pro-
vided by H.T. Orr (University of Minnesota, Minneapolis, MN). Myc-tagged 
CMV  –  ataxin-7 92Q plasmid was provided by A. La Spada (University of 
Washington, Seattle, WA). 
  Generation and expression of scFv-EM48 
  RNAs from hybridoma cells were used for RT-PCR with primers complemen-
tary to the consensus sequences ﬂ  anking the variable region heavy and 
light (V  H   and V  L  ) chains of mouse IgG (GE Healthcare). Cloned scFv cDNAs 
encoding V  L   (320 bp) and V  H   (340 bp) chains of mEM48 were linked by 
a 45-bp oligonucleotide encoding Gly-Ser (  Khoshnan et al., 2002  ), gener-
ating a 750-bp cDNA that encodes scFv-EM48. The cDNA was linked with 
the inﬂ  uenza HA or FLAG epitope and inserted into the PRK vector contain-
ing the CMV promoter for expression in cultured cells. A plasmid encoding 
the control intrabody (NAC32-myc) was provided by A. Messer (Wadsworth 
Center, New York State Department of Health, Albany, NY). HEK293 cells 
and cultured primary neurons from the cerebral cortex of embryonic day 
17 or 18 rat fetuses were transfected with scFv-EM48 using Lipofectamine 
2000 (Invitrogen). 
  For expression of scFv-EM48 via adenoviral vector, we used a 
helper-dependent adenoviral vector that contained the CMV promoter, 
scFv-EM48 cDNA, the woodchuck hepatitis virus posttranscriptional regu-
latory element, and the bovine-globin polyadenylation site. The expression 
cassette was cloned into pBGShuttle, and the corresponding adenovirus 
backbone was generated by homologous recombination in   Escherichia 
coli  , as described previously (  Shin et al., 2005  ). Generation and puriﬁ  ca-
tion of virus were performed as described previously (  Toietta et al., 2002  , 
  2005  ). We were able to generate viral scFv-EM48 with a titer of 10 
12   viral 
particles per milliliter. Adenoviral vector that did not express scFV-EM48 
served as a control. 
  Cell viability studies 
  HEK293 cells were grown in 6-well plates to 60  –  70% conﬂ  uence. After 
48 h transfection, cells were collected and then resuspended in serum-
free medium. We dispensed 50   μ  l of the cell suspension (5,000 cells) into 
a 96-well plate. Cell viability was determined by a modiﬁ  ed 3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay, the MTS assay 
(CellTiter 96; Promega), as described previously (  Zhou et al., 2003  ). For the 
SYTOX green staining assay, 0.3   μ  l of the 5 mM SYTOX green stain so-
lution (Invitrogen) was added to each well of transfected cells after 48 h 
transfection in a 6-well plate. Cells were incubated at 37  °  C in an atmo-
sphere of 5% CO  2   for 15 min and washed three times with serum-free me-
dia. Cells (10 
6   per 100   μ  l) were transferred to a 96-well plate for measuring 
ﬂ  uorescence using a ﬂ  uorescent reader (FLUOstar Galaxy; BMG Labtech 
GmbH) with an excitation wavelength of 485 nm and an emission wave-
length of 520 nm. For studying primary cultured cortical neurons, these 
cells (5 d in vitro) were transfected with PRK-scFv-EM48 and a PRK vector 
containing N-terminal htt (208 aa) with 130Q or 23Q on day 5 of culture. 
After 48 h transfection, the transfected cells were ﬁ  xed with 4% parafor-
maldehyde and examined using ﬂ  uorescence immunocytochemistry. Cells 
were stained with rabbit antibody (EM48) to htt, mouse antibody to the HA 
epitope in scFv-EM48, and Hoechst dye for detection of nuclei. We counted 
the number of neurons with disrupted neurites or fragmented nuclei under 
a ﬂ   uorescence microscope (Axiovert 200 MOT; Carl Zeiss, Inc.) and a 815  SUPPRESSION OF NEUROPIL HTT AGGREGATES BY INTRABODY   •   Wang et al.
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